Genetic Variants in PHACTR1 & LPL Mediate Restenosis Risk in Coronary Artery Patients

References

• Agrawal H, Teleb M, Lahsaei S, Carbajal L, Montanez R, Carrozza JP. Routine angiographic follow-up after coronary artery disease revascularization: is seeing believing? Curr Cardiol Rep. 2018;20(3):17. doi:10.1007/s11886-018-0957-z
   PubMed Web of Science ®Google Scholar
• Bachar BJ, Manna B. Coronary Artery Bypass Graft. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary. Circulation. 2001;103(24):3019–3041. doi:10.1161/01.CIR.103.24.3019
   PubMed Web of Science ®Google Scholar
• Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. J Geriatr Cardiol. 2018;15(2):173–184. doi:10.11909/j.issn.1671-5411.2018.02.007
   PubMedGoogle Scholar
• Kim MS, Dean LS. In-Stent Restenosis. Cardiovasc Ther. 2011;29(3):190–198. doi:10.1111/j.1755-5922.2010.00155.x
   PubMed Web of Science ®Google Scholar
• Beerkens FJ, Claessen BE, Mahan M, et al. Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nat Rev Cardiol. 2022;19(3):195–208. doi:10.1038/s41569-021-00612-6
   PubMed Web of Science ®Google Scholar
• Alexander JH, Smith PK. Coronary-artery bypass grafting. N Engl J Med. 2016;374(20):1954–1964. doi:10.1056/NEJMra1406944
   PubMed Web of Science ®Google Scholar
• Gori T. Restenosis after coronary stent implantation: cellular mechanisms and potential of endothelial progenitor cells (a short guide for the interventional cardiologist). Cells. 2022;11(13):2094. doi:10.3390/cells11132094
   PubMed Web of Science ®Google Scholar
• Xenogiannis I, Zenati M, Bhatt DL, et al. Saphenous vein graft failure: from pathophysiology to prevention and treatment strategies. Circulation. 2021;144(9):728–745. doi:10.1161/CIRCULATIONAHA.120.052163
   PubMed Web of Science ®Google Scholar
• Douglas JS, Holmes DR, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112(18):2826–2832. doi:10.1161/CIRCULATIONAHA.104.530097
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Kosinski AS, Brown CL 3rd, King SB 3rd:. Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol. 1993;21(1):6–14. doi:10.1016/0735-1097(93)90711-9
   PubMed Web of Science ®Google Scholar
• Vertes M, Nguyen DT, Szekely G, Berczi Á, Dosa E. Middle and Distal Common Carotid Artery Stenting: long-Term Patency Rates and Risk Factors for In-Stent Restenosis. Cardiovasc Intervent Radiol. 2020;43(8):1134–1142. doi:10.1007/s00270-020-02522-5
   PubMed Web of Science ®Google Scholar
• Agema WR, et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J. 2004;25(13):1163–1170. doi:10.1016/j.ehj.2004.05.006
   PubMed Web of Science ®Google Scholar
• Kastrati A, Schomig A, Elezi S, Schuuhlen H, Wilhelm M, Dirschinger J. Interlesion Dependence of the Risk for Restenosis in Patients With Coronary Stent Placement in Multiple Lesions. Circulation. 1998;97(24):2396–2401. doi:10.1161/01.cir.97.24.2396
   PubMed Web of Science ®Google Scholar
• Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care. 2004;27(4):990–994. doi:10.2337/diacare.27.4.990
   PubMed Web of Science ®Google Scholar
• Smith SA, Newby N, Bond B. Ending Restenosis: inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP. Cells. 2019;8(11):11. doi:10.3390/cells8111447
   Web of Science ®Google Scholar
• Jukema JW, Verschuren JJW, Ahmed TAN, Quax PHA. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2012;9(1):53–62. doi:10.1038/nrcardio.2011.132
   Web of Science ®Google Scholar
• Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31(1):224–230. doi:10.1016/s0735-1097(97)00450-6
   PubMed Web of Science ®Google Scholar
• Dangas G, Kuepper F. Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. Circulation. 2002;105(22):2586–2587. doi:10.1161/01.cir.0000019122.00032.df
   PubMed Web of Science ®Google Scholar
• Xu X, Liu X, Yu L, Ma J, Yu S, Ni M. Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Exp Ther Med. 2020;19(1):137–146. doi:10.3892/etm.2019.8219
   PubMed Web of Science ®Google Scholar
• Verschuren JJW, Trompet S, Postmus I, et al. Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. PLoS One. 2012;7(8):e42401. doi:10.1371/journal.pone.0042401
   PubMed Web of Science ®Google Scholar
• Vargas-Alarcón G, Ramírez-Bello J, Peña-Duque MA, Martínez-Ríos MA, Delgadillo-Rodríguez H, Fragoso JM. CASP1 Gene Polymorphisms and BAT1-NFKBIL-LTA-CASP1 Gene–Gene Interactions Are Associated with Restenosis after Coronary Stenting. Biomolecules. 2022;12(6):765. doi:10.3390/biom12060765
   PubMed Web of Science ®Google Scholar
• Liu Y-W, Huang M-S, Hsu L-W, et al. Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents. iScience. 2021;24(9):103082. doi:10.1016/j.isci.2021.103082
   PubMed Web of Science ®Google Scholar
• Zholdybayeva EV, Talzhanov YA, Aitkulova AM, et al. Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population. Hum Genomics. 2016;10(1):15. doi:10.1186/s40246-016-0077-z
   PubMedGoogle Scholar
• Verschuren JJW, Trompet S, Sampietro ML, et al. Pathway analysis using genome-wide association study data for coronary restenosis – a potential role for the PARVB gene. PLoS One. 2013;8(8):e70676. doi:10.1371/journal.pone.0070676
   PubMed Web of Science ®Google Scholar
• Youhanna S, Platt DE, Rebeiz A, et al. Parental consanguinity and family history of coronary artery disease strongly predict early stenosis. Atherosclerosis. 2010;212(2):559–563. doi:10.1016/j.atherosclerosis.2010.07.013
   PubMed Web of Science ®Google Scholar
• Hager J, Kamatani Y, Cazier J-B, et al. Genome-wide association study in a Lebanese cohort confirms PHACTR1 as a major determinant of coronary artery stenosis. PLoS One. 2012;7(6):e38663. doi:10.1371/journal.pone.0038663
   PubMed Web of Science ®Google Scholar
• Wakim V, Abi Khalil E, Salloum AK, Khazen G, Ghassibe-Sabbagh M, Zalloua PA. New susceptibility alleles associated with severe coronary artery stenosis in the Lebanese population. BMC Med Genomics. 2021;14(1):90. doi:10.1186/s12920-021-00942-x
   PubMed Web of Science ®Google Scholar
• Rader DJ, deGoma EM. Approach to the Patient with Extremely Low HDL-Cholesterol. J Clin Endocrinol Metab. 2012;97(10):3399–3407. doi:10.1210/jc.2012-2185
   PubMed Web of Science ®Google Scholar
• Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15(12):2073–2084. doi:10.1096/fj.01-0273rev
   PubMed Web of Science ®Google Scholar
• Tocci G, Barbato E, Coluccia R, et al. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. Am J Hypertens. 2016;29(4):509–518. doi:10.1093/ajh/hpv131
   PubMed Web of Science ®Google Scholar
• Tocci G, Modestino A, Coluccia R, et al. Coronary intrastent restenosis and blood pressure levels: retrospective analysis of a large cohort of patients with coronary single vessel disease: 1c.06. J Hypertens. 2010;28:e8. doi:10.1097/01.hjh.0000378255.81414.b5
   Web of Science ®Google Scholar
• Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64(5):924–928. doi:10.1161/HYPERTENSIONAHA.114.03575
   PubMed Web of Science ®Google Scholar
• Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365–372. doi:10.1161/01.CIR.104.3.365
   PubMed Web of Science ®Google Scholar
• Ross R, Epstein FH. Atherosclerosis — an inflammatory disease. N Eng J Med. 1999;340(2):115–126. doi:10.1056/nejm199901143400207
   PubMed Web of Science ®Google Scholar
• Lexis CPH, Rahel BM, Meeder JG, Zijlstra F, van derHorst IC. van der Horst ICC: the role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus. Cardiovasc Diabetol. 2009;8(1):41. doi:10.1186/1475-2840-8-41
   PubMedGoogle Scholar
• Trabattoni D, Fabbiocchi F, Montorsi P, et al. Angiographic patterns of in-stent restenosis in men and women. Ital Heart J. 2005;6(2):138–142.
   PubMedGoogle Scholar
• Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595–1599. doi:10.1161/01.atv.20.6.1595
   PubMed Web of Science ®Google Scholar
• Li TD, Zeng ZH. Adiponectin as a potential therapeutic target for the treatment of restenosis. Biomed Pharmacother. 2018;101:798–804. doi:10.1016/j.biopha.2018.03.003
   PubMed Web of Science ®Google Scholar
• Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148(3):293–300. doi:10.1530/eje.0.1480293
   PubMed Web of Science ®Google Scholar
• Jarray R, Pavoni S, Borriello L, et al. Disruption of phactr-1 pathway triggers pro-inflammatory and pro-atherogenic factors: new insights in atherosclerosis development. Biochimie. 2015;118:151–161. doi:10.1016/j.biochi.2015.09.008
   PubMed Web of Science ®Google Scholar
• Aherrahrou R, Aherrahrou Z, Schunkert H, Erdmann J. Coronary artery disease associated gene Phactr1 modulates severity of vascular calcification in vitro. Biochem Biophys Res Commun. 2017;491(2):396–402. doi:10.1016/j.bbrc.2017.07.090
   PubMed Web of Science ®Google Scholar
• Jarray R, Allain B, Borriello L, et al. Depletion of the novel protein PHACTR-1 from human endothelial cells abolishes tube formation and induces cell death receptor apoptosis. Biochimie. 2011;93(10):1668–1675. doi:10.1016/j.biochi.2011.07.010
   PubMed Web of Science ®Google Scholar
• Allain B, Jarray R, Borriello L, Leforban B, Dufour S. Neuropilin-1 regulates a new VEGF-induced gene, Phactr-1, which controls tubulogenesis and modulates lamellipodial dynamics in human endothelial cells. Cell Signal. 2012;24(1):214–223. doi:10.1016/j.cellsig.2011.09.003
   PubMed Web of Science ®Google Scholar
• Ma X, Su M, He Q, et al. PHACTR1, a coronary artery disease risk gene, mediates endothelial dysfunction. Front Immunol. 2022;13:958677. doi:10.3389/fimmu.2022.958677
   PubMed Web of Science ®Google Scholar
• Liu C, Li L, Guo D, et al. Lipoprotein lipase transporter GPIHBP1 and triglyceride-rich lipoprotein metabolism. Clinica Chimica Acta. 2018;487:33–40. doi:10.1016/j.cca.2018.09.020
   PubMed Web of Science ®Google Scholar
• Shimada M, Ishibashi S, Inaba T, et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci U S A. 1996;93(14):7242–7246. doi:10.1073/pnas.93.14.7242
   PubMed Web of Science ®Google Scholar
• Weinstock PH, Bisgaier CL, Aalto-Setälä K, et al. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest. 1995;96(6):2555–2568. doi:10.1172/jci118319
   PubMed Web of Science ®Google Scholar
• Thirunavukkarasu M, Juhasz B, Zhan L, et al. VEGFR1 (Flt-1±) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free Radic Biol Med. 2007;42(10):1487–1495. doi:10.1016/j.freeradbiomed.2007.02.011
   PubMed Web of Science ®Google Scholar
• Zhao Q, Egashira K. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol. 2004;24(12):2284–2289. doi:10.1161/01.ATV.0000147161.42956.80
   PubMed Web of Science ®Google Scholar
• Huang T, Wang L, Bai M, et al. Influence of IGF2BP2, HMG20A, and HNF1B genetic polymorphisms on the susceptibility to Type 2 diabetes mellitus in Chinese Han population. Biosci Rep. 2020;40(5). doi:10.1042/BSR20193955
   Google Scholar
• Li R, Meng S, Ji M, et al. HMG20A inhibit adipogenesis by transcriptional and epigenetic regulation of MEF2C expression. Int J Mol Sci. 2022;23(18). doi:10.3390/ijms231810559
   Web of Science ®Google Scholar
• Mikhailova SV, Ivanoshchuk DE. Innate-immunity genes in obesity. J Pers Med. 2021;11(11). doi:10.3390/jpm11111201
   Web of Science ®Google Scholar
• Qin Y, Wu K, Zhang Z, et al. NLRC3 deficiency promotes cutaneous wound healing due to the inhibition of p53 signaling. Biochim Biophys Acta Mol Basis Dis. 2022;1868(11):166518. doi:10.1016/j.bbadis.2022.166518
   PubMed Web of Science ®Google Scholar
• Chan GH, Chan E, Kwok CT, Leung GP, Lee SM, Seto SW. The role of p53 in the alternation of vascular functions. Front Pharmacol. 2022;13:981152. doi:10.3389/fphar.2022.981152
   PubMed Web of Science ®Google Scholar
• Gorgoulis VG, Pratsinis H, Zacharatos P, et al. p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab Invest. 2005;85(4):502–511. doi:10.1038/labinvest.3700241
   PubMed Web of Science ®Google Scholar